Exagen Inc. (XGN)
NASDAQ: XGNHealthcareDiagnostics & ResearchUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
XGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $201.07M
- EPS (TTM)
- -$0.82
- Dividend yield
- None
- 52-week range
- 2.59 – 12.23
- Day range
- 7.89 – 8.36
- Volume / Avg
- 234.91K / 332.40K
- Beta
- —
- Shares outstanding
- 24.23M
- Next earnings
- Nov 3, 2026
52-week range
XGN stock today
On Oct 7, XGN ended the session at $8.30, adding $0.11 (1.34%), versus the S&P 500's 0.22% decline. Shares are 32.1% below their 52-week high of $12.23, set on Oct 27, 2025 and 220.5% above the 52-week low of $2.59, in the middle of the past year's range. XGN is up 36.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 24.3%.
Exagen has posted a net loss over the last twelve months (EPS of -$0.82), so its P/E ratio is not meaningful. Exagen's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Exagen
Company profileExagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- CEO
- Mr. John Aballi
- Headquarters
- Vista, CA
- Employees
- 216
- IPO year
- 2019
- Website
- exagen.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$10.14+22.17%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.19
Exagen peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BNRBurning Rock Biotech Limited ADR | 15.18 | -5.77% | $160.09M | vs XGN |
| QUCYQuantum Cyber N.V. | 1.43 | +10.85% | $120.22M | vs XGN |
| BDSXBiodesix Inc. | 26.42 | -5.51% | $278.76M | vs XGN |
| MYGNMyriad Genetics Inc. | 4.28 | 0.00% | $409.38M | vs XGN |
| FLGTFulgent Genetics Inc. | 20.57 | -0.05% | $565.99M | vs XGN |
| CSTLCastle Biosciences Inc. | 33.00 | -1.08% | $1.01B | vs XGN |
| OPKOPKO Health Inc. | 1.39 | -4.79% | $1.04B | vs XGN |
| FRNMFreenome Inc. | 16.03 | -2.02% | $1.72B | vs XGN |
Indexes, lists and sector
Appears in lists
Exagen stock FAQ
What is Exagen's stock price today?
XGN last traded at $8.30 as of Oct 7, 4:00 PM EDT, up 1.34% on the day. Prices are delayed at least 15 minutes.
When is Exagen's next earnings date?
Exagen is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.19.
Who is Exagen's CEO?
Mr. John Aballi is the chief executive officer of Exagen Inc., which has about 216 employees.
What is the XGN 52-week high?
The 52-week high for XGN is $12.23 and the 52-week low is $2.59. The stock is currently 32.1% below its high.